Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-01-22
2008-01-22
Monshipouri, Maryam (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S789000
Reexamination Certificate
active
07320959
ABSTRACT:
The present invention provides a method for treating structural heart disease in a subject, comprising administering an effective amount of an inhibitor of CaMKII to the subject, whereby the administration of the inhibitor treats the structural heart disease in the subject. Also provided are transgenic animal models for treating structural heart disease. Further provided is a means of screening for a compound that can treat structural heart disease.
REFERENCES:
patent: 3610795 (1971-10-01), Antoine et al.
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 6518245 (2003-02-01), Anderson et al.
patent: WO 98/33491 (1998-01-01), None
Tessier et al., Circulation Research, 85(9), 810-819, 1999.
Anderson al., “KN-93, an Inhibitor of multifunctional Ca++/calmodulin-dependent protein kinase, decreases early afterdepolarizations in rabbit heart.”J Pharm Exp Ther1998; 287: 996-1006.
Bagshawe, “The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites.”Br J Cancer. Sep. 1989;60(3):275-81. Review.
Bagshawe et al., “A cytotoxic agent can be generated selectively at cancer sites.”Br J Cancer. Dec. 1988;58(6):700-703.
Battelli et al., “T lymphocyte killing by a xanthine-oxidase-containing immunotoxin.”Cancer Immunol Immunother. 1992;35(6):421-425.
Braun et al., “A Non-Selective Cation Current activated via the multifunctional Ca2+-calmodulin-dependent protein kinase in Human Epithelial cells.”J Physiol1995; 488: 37-55.
Braun et al., “The multifunctional Calcium/Calmodulin-dependent protein kinase: from form to function.”Ann Rev Physiol1995; 57: 417-445.
Brigham et al, “Expression of a prokaryotic gene in cultured lung endothelial cells lipofection with a plasmid vector”.Am J Respir Cell Mol Biol. Aug. 1989;1(2):95-100.
Brown et al., “Molecular and cellular mechanisms of receptor-mediated endocytosis.”DNA Cell Biol. Jul.-Aug. 1991;10(6):399-409. Review.
Chang et al. “Characterization of a calmodulin kinase II inhibitor protein in brain.”Proc Natl Acad Sci USASep. 1, 1998;95(18):10890-10895.
Felgner et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.”Proc Natl Acad Sci USANov. 1987;(21):7413-7417.
Gottlieb et al., “Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.”New England Journal of Medicine1998; 339: 489-497.
Hoch et al., “Identification and expression of δ-isoforms of the multifunctional Ca2+/Calmodulin-dependent protein kinase in failing and nonfailing human myocardium.”Circulation Research1999 ; 84:713-721.
Huang et al., “Transgenic expression of green fluorescence protein can cause dilated cardiomyopathy.”Nat Med2000; 6: 482-483.
Hughes et al., “Monoclonal antibody targeting of liposomes to mouse lung in vivo.”Cancer Res. Nov. 15, 1989;49(22):6214-6220.
Hunt et al., Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure).Journal of the American College of Cardiology2001; 2101-2113.
Kinugawa al., “Treatment with Dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress.”Circulation Research2000; 87: 392-398.
Litzinger et al., “Biodistribution and immunotargetability of ganglioside-stabilized dioleoylphosphatidylethanolamine liposomes.”Biochem Biophys Acta. Feb. 17, 1992;1104(1):179-87.
Miyano et al., “Purification and characterization of a brain-specific multifunctional calmodulin-dependent protein kinase from rat cerebellum.”J Biol Chem1992;267: 1198-1203.
Molkentin et al., “A calcineurin-dependent transcriptional pathway for cardiac hypertrophy,”Cell1998; 93:215-228.
Pfeffer et al., “Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction.”Ann Rev Physiol1995; 57:805-826.
Pietersz et al., “Antibody conjugates for the treatment of cancer.”Immunol Rev. Oct. 1992;129:58-80. Review.
Pitt et al., “The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.”New England Journal of Medicine1999; 341: 709-717.
Rhoads A., Friedberg F. “Sequence motifs for calmodulin recognition.”FASEB J. 1997; 11: 331-340.
Roffler et al., “Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate.”Biochem Pharmacol. Oct. 24, 1991;42(10):2062-2065.
Sam et al., “Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart.”American Journal of Physiology-Heart&Circulatory Physiology2000; 279: H422-H428.
Senter et al., “Generation of cytotoxic agents by targeted enzymes.”Bioconjug Chem. Jan.-Feb. 1993;4(1):3-9. Review.
Senter et al., “Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates.”Bioconjug Chem., Nov.-Dec. 1991;2(6):447-451.
Spencer et al., “Twenty year trends (1975-1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective.”J Am Coll Cardiol1999; 34:1378-1387.
Sussman et al., “Prevention of cardiac hypertrophy in mice by calcineurin inhibition.”Science1998; 281: 1690-1693.
Tokumitsu et al., “Activation mechanisms for Ca2+/Calmodulin-dependent protein kinase IV. Identification of a brain CaM-kinase IV kinase.”J Biol Chem1994; 269:28640-28647.
Trueblood et al., “Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin.”Circulation Research2001; 88:1080-1087.
Vaughn et al., “Post-myocardial infarction ventricular remodeling: animal and human studies.”Cardiovascular Drugs&Therapy1994; 8: 453-460.
Wu et al., “CaM kinase augments cardiac L-type Ca2+current: a cellular mechanism for long Q-T arrhythmias.”American Journal of Physiology1999; 276:H2168-H2178.
Wu et al., “Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy.”Circ. 2002;106:1288-1293.
Monshipouri Maryam
Needle & Rosenberg P.C.
Vanderbilt University
LandOfFree
Use of calmodulin kinase II inhibitors to treat myocardial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of calmodulin kinase II inhibitors to treat myocardial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of calmodulin kinase II inhibitors to treat myocardial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2798874